67
Participants
Start Date
October 30, 2022
Primary Completion Date
May 24, 2024
Study Completion Date
May 30, 2024
HU6
HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
Placebo
Placebo
Weill Cornell Medicine, New York
Johns Hopkins University, Baltimore
Wake Forest, Winston-Salem
Medical University of South Carolina, Charleston
New Generation of Medical Research, Hialeah
Broward Research Center, Pembroke Pines
The Lindner Center for Research and Education at The Christ Hospital, Cincinnati
Mayo Clinic, Rochester
Northwestern University, Chicago
The University of Chicago Medical Center, Chicago
Saint Luke's Mid America Heart Institute, Kansas City
University of Texas Southwestern, Dallas
National Heart Institute, Beverly Hills
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance
Massachusetts General Hospital, Boston
Rivus Pharmaceuticals, Inc.
INDUSTRY